Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

Under the terms of the agreement, Bayer Schering Pharma had an option until January 5, 2010 to license a specific BiTE antibody targeting an undisclosed target. The option exercise triggers a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody. Micromet will be primarily responsible for the preclinical development of the BiTE antibody, and will collaborate with Bayer through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma will assume full control of the further development and commercialization of the BiTE antibody. Micromet will receive an option exercise fee of Euro 5 million (approx. $7.5 million), and is eligible for further milestone payments of up to Euro 285 million (approx. $426 million) in total and up to double digit royalties on net sales of the BiTE antibody. In addition, Micromet will be reimbursed for its R&D expenses.

"BiTE antibodies represent a promising approach to cancer therapy," said Dr. Karl Ziegelbauer, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. "We are pleased with the progress of the program since the signing of the agreement in January of this year. We are looking forward to developing a new treatment for patients with solid tumors and to further advance novel therapeutic options in our oncology portfolio."

Jens Hennecke, Micromet's Senior Vice Presi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... LOS ANGELES , July 24, 2014 /PRNewswire/ ... medical devices, announced today that after two weeks ... experts throughout the European Union, it gained substantial ... (sub-epidermal moisture) and the clinical utility of BBI,s ... surveys, over 90 percent of the respondents drawn ...
(Date:7/24/2014)... WHIPPANY, N.J. , July 24, 2014 /PRNewswire-USNewswire/ ... Phase III trial that evaluated a 15% foam ... the topical treatment of inflammatory papules and pustules ... potential treatment option to complement the currently available ... disease causing inflammatory lesions (papules and pustules) as ...
(Date:7/24/2014)... , July 24, 2014  Market Diagnostics International ... IVD Insights™ LabFile , a data resource that ... clinical laboratory universe and identifying target In Vitro ... proprietary database that provides IVD manufacturers with accurate ... relying on clear and consistent definitions of laboratory ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
... Va., June 22 With today,s announcement that the Pharmaceutical ... grant some $80 billion in discounts to Medicare beneficiaries over ... costs, the Healthcare Compliance Packaging Council (HCPC) noted that far ... to help people take their prescription drugs properly. ...
... /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE ... that a new corporate presentation is available for review ... . The presentation includes information on ... treat swine and other influenza viruses using its L.E.A.P.S.(TM) ...
Cached Medicine Technology:HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens 2HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens 3
(Date:7/24/2014)... 2014 National Analysts Worldwide, the Philadelphia-headquartered ... will operate globally under the name, NAXION , ... Employee Stock Ownership Plan (ESOP) organization led by majority ... . The firm guides market strategy in target ... , Said McDonald, “We wanted our name to better ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... and faster, according to a new study published in ... to tackle melanoma, the most deadly form of skin ... of Manchester found that some melanoma cells are particularly ... surrounding tissue, while other melanoma cells are the opposite ... tumour, the faster growing cells ,piggy-back, along with the ...
(Date:7/24/2014)... The Biofeedback Federation of ... distribution agreement with game development company Zukor Interactive. ... groups to offer Zukor's Grind , a ... neurofeedback in European and international markets. , Zukor's ... to be used as a biofeedback/neurofeedback training tool. ...
(Date:7/24/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Even though its ... best known as Tylenol -- does not help treat lower ... The researchers found the drug was no more effective than ... acute lower back pain. Besides showing no effect in ... help in improving sleep woes tied to back pain, nor ...
Breaking Medicine News(10 mins):Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Piggy-backing cells hold clue to skin cancer growth 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3
... ... year’s edition of The Leading Physicians of the World. With a long track record of ... of the World wanted to honor the specialty so integral to the surgical team; anesthesiology. ... (PRWEB) June 26, 2010 ...
... ... by whiplash injury should be made aware of their legal entitlement to file a whiplash ... ... leading whiplash injury claims lawyers, is today warning of the need for greater awareness of ...
... ... Haitian children, mostly refugees and orphans who go all day without eating. Shelene Bryan and ... ... and her Skip1 team of volunteers were deep inside Haiti and the Dominican Republic delivering ...
... ... a renewable resource. , ... June 26, 2010 -- Laser and copier toners use over 146,000,000 gallons of oil per ... or Forestry products, therefore, eliminating the need for petroleum products. The term bio-product is ...
... studying and treating disease and for the practice of ... the cells that may one day be transplanted into ... studies going on worldwide, scientists at the UCLA Broad ... X chromosome inactivation take place in very early passages ...
... By Maryann Mott HealthDay Reporter , FRIDAY, June ... chuckle out of watching their dog sleep while its paws race ... in dreamland, and scientists say they were right: Pets do ... of past events replay in their minds much the same way ...
Cached Medicine News:Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 2Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 3Health News:Whiplash Claims Warns on Awareness of Personal Injury Compensation Entitlement 2Health News:Shelene Bryan and Skip1.org Help Build Kitchen for Haitian Orphans 2Health News:Great Office Buys Announces the Addition of Elite Brand Bio-Based Toners to their Product Line 2Health News:Chromosomal variations found in early passage female embryonic stem cells 2Health News:Chromosomal variations found in early passage female embryonic stem cells 3Health News:Where Do Pets Go When They Dream? 2Health News:Where Do Pets Go When They Dream? 3
... heavy duty, controlled stretch knee support that ... allowing full range of motion. The ... the knee, and help to keep the ... This is an excellent support for ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Scoring: , One of the outstanding features ... our patented Three-Dimensional Molding Technology. , This ... brace which effectively controls the bunching and ... comfort to the wearer. , ...
... new padding system from Innovation Sports. Exceptionally ... contours to the unique anatomy of each ... Gel Fit's proprietary Octogrip™ Anti-Slip System improves ... when the brace is strapped on. Gel ...
Medicine Products: